Fig. 1: Bioinformatics analysis and clinical practice evidenced that RLPS patients could benefit from a combination of anlotinib and eribulin. | Cell Death Discovery

Fig. 1: Bioinformatics analysis and clinical practice evidenced that RLPS patients could benefit from a combination of anlotinib and eribulin.

From: Combination of eribulin and anlotinib exerts synergistic cytotoxicity in retroperitoneal liposarcoma by inducing endoplasmic reticulum stress

Fig. 1

A Major targets of anlotinib are upregulated in liposarcoma tissues (n = 46) compared to normal fat tissue (n = 9). Box plots were generated from the GSE21122 dataset, wherein mRNA level is presented in logarithmic scale. Statistical test: Wilcoxon rank test, *p < 0.05; **p < 0.01; ***p < 0.001. B A patient with DDLPS achieved partial regression after receiving the combination of anlotinib and eribulin. C A patient with WDLPS first achieved stable disease after anlotinib treatment and then achieved partial regression following eribulin co-administration. ICB immune checkpoint blockade.

Back to article page